Carcinotech is paving the way to the future of effective cancer treatments with its mission to work with global stakeholders to accelerate drug discovery and bring more effective treatments to market.
As the battle against cancer continues, there has been some promising progress thanks to developments in science and technology. One company contributing to the cause is Carcinotech; an innovative MedTech company that aims to provide accessible, personalised medicine testing to individuals suffering from cancer, with the aim of improving their chance of survival.
With a mission to be at the forefront of patient-specific drug discovery and screening, Carcinotech manufactures 3D-printed tumours that support rapid, ethical, and accurate drug discovery, screening, and pre-clinical testing. The mini tumours are 3D-printed using patient-derived biopsies, cancer stem cells, immune cells and established cell lines.
The company works with global partners, leading pharma companies, surgeons, pathologists, clinicians and industry leaders to accelerate drug discovery and bring more effective cancer treatments to market.
CEO and founder Ishani Malhotra (pictured), along with her brilliant team, have developed pioneering oncology biotechnology with the potential to make a significant impact in discovery, screening, and pre-clinical testing.
The mission-driven business, which is based at the Roslin Innovation Centre on the outskirts of Edinburgh, has already established partnerships with industry organisations like Cancer Research UK, global pharma groups and a major US-based clinical research organisation (CRO).
With ambitions to grow its team, extend its commercial partnerships in Europe and North America, and appoint a scientific advisory committee, Carcinotech secured a £1.6 million investment from leading Scotland-based investors.
The investment round, which was led by TRICAPITAL alongside SIS Ventures, Gabriel Investments, EoS Advisory, Alba Equity, and Scottish Enterprise, aims to accelerate commercialisation and international market expansion.
With its strong mission and impressive traction to date, Carcinotech is certainly one of the most exciting early-stage companies to come out of the Scottish life sciences sector in recent years. We look forward to being part of the journey.
“Scotland has a world-renowned track record in oncology R&D, and it’s great to see Carcinotech making an impression in international markets. Ishani (Founder and CEO) and her team are now positioned to step up activity in Europe and North America, and it’s great for the company to be doing that with such a supportive group of investors.”
Albert Nicholl, Chairman, Carcinotech
Carcinotech secures £1.6m of new investment from leading Scottish investorsRead more about Carcinotech secures £1.6m of new investment from leading Scottish investors
Medical device specialist Nebu~Flow secures £1.7m investmentRead more about Medical device specialist Nebu~Flow secures £1.7m investment
SIS Ventures appoints new investment manager to fuel growthRead more about SIS Ventures appoints new investment manager to fuel growth